Literature DB >> 15065619

Sirolimus-associated diffuse alveolar hemorrhage.

Nicholas E Vlahakis1, Otis B Rickman, Timothy Morgenthaler.   

Abstract

Sirolimus is an immunosuppressive medication used in transplant recipients. To our knowledge, we describe the third reported case of alveolar hemorrhage in association with sirolimus. Fever, dyspnea, hemoptysis, and lung infiltrates resolved rapidly with cessation of sirolimus therapy both initially and after reinstitution of the drug. Unlike previous reports, our patient had no evidence of lymphocytic alveolitis but rather marked macrophage hemosiderosis, suggesting that sirolimus pulmonary toxicity may manifest through 2 separate mechanisms. Our case highlights an uncommon but potentially lethal manifestation of sirolimus pulmonary toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065619     DOI: 10.4065/79.4.541

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review.

Authors:  Abdelkarim Waness; Tarek Aldabbagh; Mohammed Harakati
Journal:  BMJ Case Rep       Date:  2009-03-17

2.  Derivation and validation of automated electronic search strategies to identify pertinent risk factors for postoperative acute lung injury.

Authors:  Anas Alsara; David O Warner; Guangxi Li; Vitaly Herasevich; Ognjen Gajic; Daryl J Kor
Journal:  Mayo Clin Proc       Date:  2011-05       Impact factor: 7.616

3.  Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.

Authors:  Rosalba Siracusa; Irene Paterniti; Marika Cordaro; Rosalia Crupi; Giuseppe Bruschetta; Michela Campolo; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Mol Neurobiol       Date:  2017-03-29       Impact factor: 5.590

Review 4.  Hemoptysis in Renal Transplant Recipients.

Authors:  Vasiliki Epameinondas Georgakopoulou; Aikaterini Gkoufa; Aikaterini Aravantinou; Nikolaos Garmpis; Konstantinos Mantzouranis; Serafeim Chlapoutakis; Pagona Sklapani; Anna Garmpi; Nikolaos Trakas; Christos Damaskos
Journal:  Acta Med Litu       Date:  2021-07-29

Review 5.  mTOR inhibitors and renal allograft: Yin and Yang.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Valentina Masola; Giovanni Gambaro; Antonio Lupo
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

6.  Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.

Authors:  Sean Kirby; Anjali Satoskar; Sergey Brodsky; Amy Pope-Harman; David Nunley; Charles Hitchcock; Ronald Pelletier; Patrick Ross; Tibor Nadasdy; Konstantin Shilo
Journal:  Diagn Pathol       Date:  2012-03-14       Impact factor: 2.644

Review 7.  Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.

Authors:  Gianluigi Zaza; Paola Tomei; Paolo Ria; Simona Granata; Luigino Boschiero; Antonio Lupo
Journal:  Clin Dev Immunol       Date:  2013-09-19

8.  In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets.

Authors:  Simona Granata; Gloria Santoro; Valentina Masola; Paola Tomei; Fabio Sallustio; Paola Pontrelli; Matteo Accetturo; Nadia Antonucci; Pierluigi Carratù; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2018-04-20       Impact factor: 5.923

9.  Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus.

Authors:  Ahmed M Alkhunaizi; Thamer H Al-Khouzaie; Ahmed I Alsagheir
Journal:  Respir Med Case Rep       Date:  2020-06-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.